KEAP1 and metabolic syndrome: As diosmetin is known to alleviated stroke volume, ejection fraction, fractional shortening, LV hypertrophy and superoxide (O2·−) formation in high-fat diet-induced metabolic syndrome (MS) rats [24], our data indicate that diosmetin plays a protective role in myocardial remodeling by regulating of p62-Keap1-NRF2 signaling pathways and hence reducing ROS production.